Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age

NCT05267613 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05267613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05267613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2022
Completion date
August 10, 2026
Enrollment
53 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

erosive esophagitis